

RELEASE – COMMUNICATION

Zug, June 24th 2017

Wockhardt Limited (India) and its Subsidiaries settle with Teva and its Affiliate a commercial litigation in the High Court, London (UK)

On June 22nd 2017, Wockhardt Limited (WL) announced that, WL and two subsidiaries, Wockhardt UK Holdings Limited and CP Pharmaceuticals Limited (CP), in the United Kingdom have settled an ongoing commercial litigation before the High Court in London, United Kingdom in relation to a supply contract for a drug named Trisenox.

The dispute between the parties was in respect of the price charged by CP to its counterparty to the contract, Cephalon Inc, (Cephalon) an affiliate of Teva Pharmaceuticals USA, Inc. (Teva). The proceedings commenced in September 2015.

Under the above referred settlement between the parties, CP has agreed to waive its claim for the outstanding trade receivable of GBP 20 mn and accordingly dropped its counterclaim for the said amount and further paid a sum of GBP 23 mn to Teva and Cephalon by way of full and final settlement of Teva's claims. The High Court has accepted the settlement between the parties and a Consent Order was issued on June 21, 2017. Pursuant to this settlement the ongoing litigation stands closed and all claims are dismissed.

Stock Listing

The registered shares of Wockhardt Bio AG are traded at the BX Bern eXchange.

Ticker Symbols:

WBIO (Telekurs)

Securities nummer 19304250

ISIN CH 019 304 250 1